See more : Silverback Therapeutics, Inc. (SBTX) Income Statement Analysis – Financial Results
Complete financial analysis of GBS Inc. (GBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GBS Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Radiant Logistics, Inc. (RLGT) Income Statement Analysis – Financial Results
- ROCKELLE CORP (RKLC) Income Statement Analysis – Financial Results
- Tyroon Tea Company Limited (TYROON.BO) Income Statement Analysis – Financial Results
- Tohoku Steel Co., Ltd. (5484.T) Income Statement Analysis – Financial Results
- Adecco Group AG (ADEN.SW) Income Statement Analysis – Financial Results
GBS Inc. (GBS)
About GBS Inc.
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.26M | 437.15K | 1.98M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 930.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 326.67K | 437.15K | 1.98M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 25.99% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 3.85M | 3.84M | 588.21K | 3.18M | 2.53M |
| General & Administrative | 0.00 | 4.92M | 3.72M | 2.43M | 3.55M | 2.08M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.03M | 4.92M | 3.72M | 2.43M | 3.55M | 2.08M |
| Other Expenses | 0.00 | -437.15K | -1.98M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.03M | 8.34M | 5.57M | 3.02M | 6.73M | 4.60M |
| Cost & Expenses | 8.96M | 8.34M | 5.57M | 2.83M | 6.73M | 4.60M |
| Interest Income | 9.68K | 14.43K | 13.81K | 97.00 | 188.00 | 564.00 |
| Interest Expense | -223.53K | 7.54K | 1.09M | 457.75K | 664.84K | 453.87K |
| Depreciation & Amortization | -966.73K | 38.36K | -370.20K | 150.96K | 57.88K | 36.96K |
| EBITDA | -13.56M | -8.30M | -5.94M | -2.68M | -6.67M | -4.57M |
| EBITDA Ratio | -1,079.03% | -1,898.34% | -300.11% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.60M | -8.34M | -5.57M | -2.83M | -6.73M | -4.60M |
| Operating Income Ratio | -1,002.11% | -1,907.11% | -281.42% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.96M | 2.90K | -1.49M | -335.96K | -664.65K | -453.31K |
| Income Before Tax | -10.63M | -8.33M | -7.06M | -3.16M | -7.39M | -5.06M |
| Income Before Tax Ratio | -845.89% | -1,906.45% | -356.49% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -38.36K | -22.92K | -29.17K | -57.69K | -36.39K |
| Net Income | -10.63M | -8.30M | -7.04M | -3.13M | -7.34M | -5.02M |
| Net Income Ratio | -845.89% | -1,897.68% | -355.33% | 0.00% | 0.00% | 0.00% |
| EPS | -10.58 | -0.57 | -0.52 | -0.28 | -0.65 | -0.44 |
| EPS Diluted | -10.58 | -0.57 | -0.52 | -0.28 | -0.65 | -0.44 |
| Weighted Avg Shares Out | 1.00M | 14.67M | 13.58M | 11.29M | 11.29M | 11.29M |
| Weighted Avg Shares Out (Dil) | 1.00M | 14.67M | 13.58M | 11.29M | 11.29M | 11.29M |
GBS Inc.: Pioneering Non-Invasive, Real-Time Diagnostic Testing
GBS Awarded $4.7 Million Australian Federal Government Science Grant To Manufacture Biosensor Technology
Hot Penny Stocks to Buy Under $5? 3 You Might Not Have Heard Of
GBS Stock Price: Over 45% Increase Pre-Market Explanation
Patients Living With Diabetes Voice Eagerness for ‘Finger-Prick' Alternative in Global Glucose Monitoring Survey
GBS Inc. Reports First Quarter 2021 Financial Results and Recent Business Highlights
GBS, Inc. Receives Approval to Commence Validation Clinical Study for Rapid SARS-CoV-2 Diagnostic Test
GBS Inc. Enters Sponsored Research Agreement with Johns Hopkins Bloomberg School of Public Health To Accelerate Development of Saliva-Based Diagnostic Tests
GBS, Inc. Announces Closing of Upsized $21.6 Million Initial Public Offering
UPDATE - GBS Inc. Announces Pricing of $21.6 Million Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports